http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108727584-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d62d92aaf868f7c4e0a1c6445ca2a3c1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-33317 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-33396 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G65-33327 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G65-333 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b67171b6bdb395ea74a1287761bce66a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10f8d7abc332d415f0b58b06487f2bcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f2ff223b97dba1e3a8c85e5f28bf585 |
| publicationDate | 2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108727584-A |
| titleOfInvention | anticancer conjugates |
| abstract | The present invention discloses a multi-branched drug conjugate with the following structural formula (I) or a pharmaceutically acceptable salt thereof: R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3-8, wherein L is: The symbol "*" represents the connection point between the multivalent linker L and the targeting molecule T, "#" represents the connection point between the multivalent linker L and the active agent D, and "%" represents the connection point between the multivalent linker L and POLY, wherein, l is any integer between 2-20, m and n are any integer between 0-10 respectively; T is GE11; D is a camptothecin drug. Compared with the small molecule anticancer compound, the conjugate of the present invention has stronger tumor inhibitory ability, and the suitable solid tumor types include colon cancer, breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, brain glioma and breast and ovarian cancer. , malignant sarcomas, carcinomas and lymphomas of the colon, kidney, bile duct, lung and brain. |
| priorityDate | 2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.